Loading
A phase 1/2 trial of TQB6411 in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection is a phase 1/2 interventional study registered as NCT07367529 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 465 participants planned, started 2026-02-26 and due to reach its primary completion in 2028-12. Interventions recorded: TQB6411 for Injection.
Shares TQB6411, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.